Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 14/20 | 0.67 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.67 |
| ▸ | PI4KA | P42356 | 1/20 | 0.55 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.55 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.55 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL90990 | 1.00 | ADK (0.67) | ADKSLC29A1PI4KAPI4K2BPI4K2A | |
| SCHEMBL67029 | 1.00 | ADK (0.67) | ADKSLC29A1PI4KAPI4K2BPI4K2A | |
| SCHEMBL68579 | 0.91 | ADK (0.56) | ADKSLC29A1PI4KAPI4K2BPI4K2A | |
| SCHEMBL18572215 | 0.88 | PI4KA (0.56) | ADKSLC29A1PI4KAPI4K2BPI4K2A | |
| SCHEMBL90988 | 0.88 | PI4KA (0.66) | ADKSLC29A1PI4KAPI4K2BPI4K2A | |
| SCHEMBL60676 | 0.88 | PI4KA (0.66) | ADKSLC29A1PI4KAPI4K2BPI4K2A | |
| SCHEMBL67726 | 0.88 | PI4KA (0.66) | ADKSLC29A1PI4KAPI4K2BPI4K2A | |
| SCHEMBL18009754 | 0.88 | PI4KA (0.55) | ADKSLC29A1PI4KAPI4K2BPI4K2A | |
| SCHEMBL18535300 | 0.88 | PI4KA (0.55) | ADKSLC29A1PI4KAPI4K2BPI4K2A | |
| SCHEMBL29772297 | 0.88 | PI4KA (0.55) | ADKSLC29A1PI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3341368-B1 | NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-10-06 | — | — | EP | disclosed |
| EP-3426664-B1 | SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-06-30 | — | — | EP | disclosed |
| US-20200289539-A1 | NOVEL SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-09-17 | — | — | US | disclosed |
| WO-2017153186-A1 | SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-09-14 | — | — | WO | disclosed |
| EP-1756313-B1 | SEQUENCE-SPECIFIC DETECTION OF METHYLATION IN BIOMOLECULES | MAX PLANCK GESELLSCHAFT (DE) | 2012-06-06 | — | — | EP | disclosed |
| US-8129106-B2 | Sequence-specific detection of methylation in biomolecules | Max-Planck-Geselischaft zur Forderung der Wissenschaften E.V. (DE) | 2012-03-06 | — | — | US | disclosed |
| US-20110165564-A1 | SEQUENCE-SPECIFIC DETECTION OF METHYLATION IN BIOMOLECULES | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200289539-A1 | NOVEL SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | ADK 284/4885SLC29A1 108/4885PI4KA 2576/4885 |
| US-20110165564-A1 | SEQUENCE-SPECIFIC DETECTION OF METHYLATION IN BIOMOLECULES | DNMT1, MAT2B, AHCY | ADK 291/4885SLC29A1 804/4885PI4KA 4743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.